PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
17452643-1	2007	The signaling molecule nitric oxide (NO), first described as endothelium-derived relaxing factor (EDRF), acts as physiological activator of NO-sensitive guanylyl cyclase (NO-GC) in the cardiovascular, gastrointestinal, and nervous systems.	Nitric Oxide	23-35	alpha hemoglobin stabilizing protein	Mus musculus	61-96
17607360-2	2007	alphaHb-stabilizing protein (AHSP) binds free alpha subunits reversibly to maintain their structure and limit their ability to generate reactive oxygen species.	Reactive Oxygen Species	136-159	alpha hemoglobin stabilizing protein	Mus musculus	0-27
17607360-2	2007	alphaHb-stabilizing protein (AHSP) binds free alpha subunits reversibly to maintain their structure and limit their ability to generate reactive oxygen species.	Reactive Oxygen Species	136-159	alpha hemoglobin stabilizing protein	Mus musculus	29-33
17452643-1	2007	The signaling molecule nitric oxide (NO), first described as endothelium-derived relaxing factor (EDRF), acts as physiological activator of NO-sensitive guanylyl cyclase (NO-GC) in the cardiovascular, gastrointestinal, and nervous systems.	Nitric Oxide	23-35	alpha hemoglobin stabilizing protein	Mus musculus	98-102
8770106-3	1996	EDRF mediates the response to ACh and is a basally released dilator and antiplatelet paracrine substance.	Acetylcholine	30-33	alpha hemoglobin stabilizing protein	Mus musculus	0-4
17258180-11	2007	ACh caused dilation via endothelial-derived relaxing factor (EDRF) in WT mice and via endothelial-derived hyperpolarizing factor (EDHF) in eNOS(-/-) mice.	Acetylcholine	0-3	alpha hemoglobin stabilizing protein	Mus musculus	24-59
17258180-11	2007	ACh caused dilation via endothelial-derived relaxing factor (EDRF) in WT mice and via endothelial-derived hyperpolarizing factor (EDHF) in eNOS(-/-) mice.	Acetylcholine	0-3	alpha hemoglobin stabilizing protein	Mus musculus	61-65
17258180-11	2007	ACh caused dilation via endothelial-derived relaxing factor (EDRF) in WT mice and via endothelial-derived hyperpolarizing factor (EDHF) in eNOS(-/-) mice.	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	53-59	alpha hemoglobin stabilizing protein	Mus musculus	61-65
17258180-14	2007	Sepsis impairs both EDRF- and EDHF-mediated dilation in response to ACh.	Acetylcholine	68-71	alpha hemoglobin stabilizing protein	Mus musculus	20-24
16339656-2	2005	Alpha hemoglobin-stabilizing protein (AHSP) is an abundant erythroid protein that specifically binds free alphaHb, stabilizes its structure, and limits its ability to participate in chemical reactions that generate reactive oxygen species.	alphahb	106-113	alpha hemoglobin stabilizing protein	Mus musculus	0-36
16339656-2	2005	Alpha hemoglobin-stabilizing protein (AHSP) is an abundant erythroid protein that specifically binds free alphaHb, stabilizes its structure, and limits its ability to participate in chemical reactions that generate reactive oxygen species.	alphahb	106-113	alpha hemoglobin stabilizing protein	Mus musculus	38-42
16339656-2	2005	Alpha hemoglobin-stabilizing protein (AHSP) is an abundant erythroid protein that specifically binds free alphaHb, stabilizes its structure, and limits its ability to participate in chemical reactions that generate reactive oxygen species.	Reactive Oxygen Species	215-238	alpha hemoglobin stabilizing protein	Mus musculus	0-36
16339656-2	2005	Alpha hemoglobin-stabilizing protein (AHSP) is an abundant erythroid protein that specifically binds free alphaHb, stabilizes its structure, and limits its ability to participate in chemical reactions that generate reactive oxygen species.	Reactive Oxygen Species	215-238	alpha hemoglobin stabilizing protein	Mus musculus	38-42
16339656-6	2005	We used biochemical, spectroscopic, and crystallographic methods to examine how AHSP stabilizes alphaHb.	alphahb	96-103	alpha hemoglobin stabilizing protein	Mus musculus	80-84
16339656-7	2005	AHSP binds the G and H helices of alphaHb on a surface that largely overlaps with the alpha1-beta1 interface of HbA.	alphahb	34-41	alpha hemoglobin stabilizing protein	Mus musculus	0-4
16339656-8	2005	This result explains previous findings that betaHb can competitively displace AHSP from alphaHb to form HbA tetramer.	betahb	44-50	alpha hemoglobin stabilizing protein	Mus musculus	78-82
16339656-8	2005	This result explains previous findings that betaHb can competitively displace AHSP from alphaHb to form HbA tetramer.	alphahb	88-95	alpha hemoglobin stabilizing protein	Mus musculus	78-82
16339656-9	2005	Remarkably, binding of AHSP to oxygenated alphaHb induces dramatic conformational changes and converts the heme-bound iron to an oxidized hemichrome state in which all six coordinate positions are occupied.	alphahb	42-49	alpha hemoglobin stabilizing protein	Mus musculus	23-27
16339656-9	2005	Remarkably, binding of AHSP to oxygenated alphaHb induces dramatic conformational changes and converts the heme-bound iron to an oxidized hemichrome state in which all six coordinate positions are occupied.	Heme	107-111	alpha hemoglobin stabilizing protein	Mus musculus	23-27
16339656-9	2005	Remarkably, binding of AHSP to oxygenated alphaHb induces dramatic conformational changes and converts the heme-bound iron to an oxidized hemichrome state in which all six coordinate positions are occupied.	Iron	118-122	alpha hemoglobin stabilizing protein	Mus musculus	23-27
16339656-10	2005	This structure limits the reactivity of heme iron, providing a mechanism by which AHSP stabilizes alphaHb.	Heme	40-44	alpha hemoglobin stabilizing protein	Mus musculus	82-86
16339656-10	2005	This structure limits the reactivity of heme iron, providing a mechanism by which AHSP stabilizes alphaHb.	Iron	45-49	alpha hemoglobin stabilizing protein	Mus musculus	82-86
16339656-10	2005	This structure limits the reactivity of heme iron, providing a mechanism by which AHSP stabilizes alphaHb.	alphahb	98-105	alpha hemoglobin stabilizing protein	Mus musculus	82-86
16339656-12	2005	Moreover, understanding how AHSP stabilizes alphaHb provides a theoretical basis for new strategies to inhibit the damaging effects of free alphaHb that accumulates in beta-thalassemia.	alphahb	44-51	alpha hemoglobin stabilizing protein	Mus musculus	28-32
16339656-12	2005	Moreover, understanding how AHSP stabilizes alphaHb provides a theoretical basis for new strategies to inhibit the damaging effects of free alphaHb that accumulates in beta-thalassemia.	alphahb	140-147	alpha hemoglobin stabilizing protein	Mus musculus	28-32
8996510-1	1997	BACKGROUND AND PURPOSE: Tetrahydrobiopterin (THBP) is an essential cofactor for nitric oxide synthase (NOS), which is responsible for the synthesis of the endothelium-derived relaxing factor (EDRF) responsible for mediating the vasorelaxation produced by acetylcholine (ACh).	sapropterin	24-43	alpha hemoglobin stabilizing protein	Mus musculus	155-190
8996510-1	1997	BACKGROUND AND PURPOSE: Tetrahydrobiopterin (THBP) is an essential cofactor for nitric oxide synthase (NOS), which is responsible for the synthesis of the endothelium-derived relaxing factor (EDRF) responsible for mediating the vasorelaxation produced by acetylcholine (ACh).	sapropterin	24-43	alpha hemoglobin stabilizing protein	Mus musculus	192-196
8996510-1	1997	BACKGROUND AND PURPOSE: Tetrahydrobiopterin (THBP) is an essential cofactor for nitric oxide synthase (NOS), which is responsible for the synthesis of the endothelium-derived relaxing factor (EDRF) responsible for mediating the vasorelaxation produced by acetylcholine (ACh).	sapropterin	45-49	alpha hemoglobin stabilizing protein	Mus musculus	155-190
8996510-1	1997	BACKGROUND AND PURPOSE: Tetrahydrobiopterin (THBP) is an essential cofactor for nitric oxide synthase (NOS), which is responsible for the synthesis of the endothelium-derived relaxing factor (EDRF) responsible for mediating the vasorelaxation produced by acetylcholine (ACh).	sapropterin	45-49	alpha hemoglobin stabilizing protein	Mus musculus	192-196
8996510-1	1997	BACKGROUND AND PURPOSE: Tetrahydrobiopterin (THBP) is an essential cofactor for nitric oxide synthase (NOS), which is responsible for the synthesis of the endothelium-derived relaxing factor (EDRF) responsible for mediating the vasorelaxation produced by acetylcholine (ACh).	Acetylcholine	255-268	alpha hemoglobin stabilizing protein	Mus musculus	155-190
8996510-1	1997	BACKGROUND AND PURPOSE: Tetrahydrobiopterin (THBP) is an essential cofactor for nitric oxide synthase (NOS), which is responsible for the synthesis of the endothelium-derived relaxing factor (EDRF) responsible for mediating the vasorelaxation produced by acetylcholine (ACh).	Acetylcholine	270-273	alpha hemoglobin stabilizing protein	Mus musculus	155-190
7545787-1	1995	Nitric oxide (NO), a potent vasodilator produced by endothelial cells, is thought to be the endothelium-dependent relaxing factor (EDRF) which mediates vascular relaxation in response to acetylcholine, bradykinin and substance P in many vascular beds.	Nitric Oxide	0-12	alpha hemoglobin stabilizing protein	Mus musculus	92-129
8806852-4	1996	It is rapidly transformed to nitric oxide (NO) which is thought to be endothelium-derived relaxing factor (EDRF).	Nitric Oxide	29-41	alpha hemoglobin stabilizing protein	Mus musculus	70-105
8806852-4	1996	It is rapidly transformed to nitric oxide (NO) which is thought to be endothelium-derived relaxing factor (EDRF).	Nitric Oxide	29-41	alpha hemoglobin stabilizing protein	Mus musculus	107-111
7545787-1	1995	Nitric oxide (NO), a potent vasodilator produced by endothelial cells, is thought to be the endothelium-dependent relaxing factor (EDRF) which mediates vascular relaxation in response to acetylcholine, bradykinin and substance P in many vascular beds.	Acetylcholine	187-200	alpha hemoglobin stabilizing protein	Mus musculus	92-129
1618948-1	1992	Thimerosal causes synthesis and/or release of both endothelium-derived relaxing factor (EDRF) and prostaglandins from conductance vessels in vitro.	Thimerosal	0-10	alpha hemoglobin stabilizing protein	Mus musculus	51-86
8403896-13	1993	We shall consider possible roles for PQQ in the biosynthesis of nitric oxide (NO, endothelium-derived relaxing factor, EDRF) from L-arginine and in NO removal by superoxide.	PQQ Cofactor	37-40	alpha hemoglobin stabilizing protein	Mus musculus	119-123
7906075-3	1993	EDRF production was blunted in the absence of extracellular L-arginine and in the presence of N omega-nitro-L-arginine (L-NAG; 200 microM).	Arginine	60-70	alpha hemoglobin stabilizing protein	Mus musculus	0-4
7906075-3	1993	EDRF production was blunted in the absence of extracellular L-arginine and in the presence of N omega-nitro-L-arginine (L-NAG; 200 microM).	Nitroarginine	94-118	alpha hemoglobin stabilizing protein	Mus musculus	0-4
7906075-4	1993	Inhibition of endothelial EDRF production by removal of arginine or addition of L-NAG was associated with a significant decrease of renin secretion from the cocultures while the same regimen had no effect on renin secretion from JG cells alone.	Arginine	56-64	alpha hemoglobin stabilizing protein	Mus musculus	26-30
7906075-5	1993	Exogenous generation of nitric oxide by the addition of sodium nitroprusside (100 microM) stimulated renin secretion in the cocultures both at normal and inhibited EDRF formation as well as from juxtaglomerular cells alone.	Nitric Oxide	24-36	alpha hemoglobin stabilizing protein	Mus musculus	164-168
7906075-5	1993	Exogenous generation of nitric oxide by the addition of sodium nitroprusside (100 microM) stimulated renin secretion in the cocultures both at normal and inhibited EDRF formation as well as from juxtaglomerular cells alone.	Nitroprusside	56-76	alpha hemoglobin stabilizing protein	Mus musculus	164-168
1618948-1	1992	Thimerosal causes synthesis and/or release of both endothelium-derived relaxing factor (EDRF) and prostaglandins from conductance vessels in vitro.	Thimerosal	0-10	alpha hemoglobin stabilizing protein	Mus musculus	88-92
1618948-5	1992	Dilation was also eliminated by topical L-NMMA, a reported inhibitor of EDRF synthesis.	omega-N-Methylarginine	40-46	alpha hemoglobin stabilizing protein	Mus musculus	72-76
1618948-8	1992	The ability of thimerosal to dilate arterioles was eliminated not only by treatments thought to eliminate synthesis/release of EDRF, but also by cyclooxygenase inhibitors.	Thimerosal	15-25	alpha hemoglobin stabilizing protein	Mus musculus	127-131
1618948-11	1992	We conclude that the dilating effects of thimerosal on diameter require two endothelium-derived agents: EDRF and one or more prostaglandins acting in concert.	Thimerosal	41-51	alpha hemoglobin stabilizing protein	Mus musculus	104-108
1618948-12	1992	However, the inhibiting effect of thimerosal on local platelet adhesion/aggregation appears to be caused only by an increase in EDRF at the injured site.	Thimerosal	34-44	alpha hemoglobin stabilizing protein	Mus musculus	128-132
1717509-4	1991	Indomethacin (10 microM) and NG-monomethyl-l-arginine (NMMA) (1 mM) used to inhibit cyclooxygenase activity and production of endothelium-derived relaxing factor (EDRF) decreased spontaneous renin release in the presence of endothelial cells only, but had no effect on forskolin stimulated renin secretion.	omega-N-Methylarginine	29-53	alpha hemoglobin stabilizing protein	Mus musculus	163-167
1717509-4	1991	Indomethacin (10 microM) and NG-monomethyl-l-arginine (NMMA) (1 mM) used to inhibit cyclooxygenase activity and production of endothelium-derived relaxing factor (EDRF) decreased spontaneous renin release in the presence of endothelial cells only, but had no effect on forskolin stimulated renin secretion.	omega-N-Methylarginine	55-59	alpha hemoglobin stabilizing protein	Mus musculus	126-161
1717509-4	1991	Indomethacin (10 microM) and NG-monomethyl-l-arginine (NMMA) (1 mM) used to inhibit cyclooxygenase activity and production of endothelium-derived relaxing factor (EDRF) decreased spontaneous renin release in the presence of endothelial cells only, but had no effect on forskolin stimulated renin secretion.	Indomethacin	0-12	alpha hemoglobin stabilizing protein	Mus musculus	126-161
1717509-4	1991	Indomethacin (10 microM) and NG-monomethyl-l-arginine (NMMA) (1 mM) used to inhibit cyclooxygenase activity and production of endothelium-derived relaxing factor (EDRF) decreased spontaneous renin release in the presence of endothelial cells only, but had no effect on forskolin stimulated renin secretion.	Indomethacin	0-12	alpha hemoglobin stabilizing protein	Mus musculus	163-167
1717509-4	1991	Indomethacin (10 microM) and NG-monomethyl-l-arginine (NMMA) (1 mM) used to inhibit cyclooxygenase activity and production of endothelium-derived relaxing factor (EDRF) decreased spontaneous renin release in the presence of endothelial cells only, but had no effect on forskolin stimulated renin secretion.	omega-N-Methylarginine	55-59	alpha hemoglobin stabilizing protein	Mus musculus	163-167
1717509-4	1991	Indomethacin (10 microM) and NG-monomethyl-l-arginine (NMMA) (1 mM) used to inhibit cyclooxygenase activity and production of endothelium-derived relaxing factor (EDRF) decreased spontaneous renin release in the presence of endothelial cells only, but had no effect on forskolin stimulated renin secretion.	Colforsin	269-278	alpha hemoglobin stabilizing protein	Mus musculus	126-161
1717509-4	1991	Indomethacin (10 microM) and NG-monomethyl-l-arginine (NMMA) (1 mM) used to inhibit cyclooxygenase activity and production of endothelium-derived relaxing factor (EDRF) decreased spontaneous renin release in the presence of endothelial cells only, but had no effect on forskolin stimulated renin secretion.	omega-N-Methylarginine	29-53	alpha hemoglobin stabilizing protein	Mus musculus	126-161
2508448-0	1989	Inhibition of platelet-derived mitogen release by nitric oxide (EDRF).	Nitric Oxide	50-62	alpha hemoglobin stabilizing protein	Mus musculus	64-68
2255125-12	1990	Evidence in pial arterioles for the basal release of EDRF for acetylcholine, comes from our data showing that L-NMMA constricts these arterioles.	Acetylcholine	62-75	alpha hemoglobin stabilizing protein	Mus musculus	53-57
2255125-12	1990	Evidence in pial arterioles for the basal release of EDRF for acetylcholine, comes from our data showing that L-NMMA constricts these arterioles.	omega-N-Methylarginine	110-116	alpha hemoglobin stabilizing protein	Mus musculus	53-57
2255125-13	1990	L-NMMA is a known inhibitor of synthesis of "classical" EDRF from L-arginine.	omega-N-Methylarginine	0-6	alpha hemoglobin stabilizing protein	Mus musculus	56-60
2255125-13	1990	L-NMMA is a known inhibitor of synthesis of "classical" EDRF from L-arginine.	Arginine	66-76	alpha hemoglobin stabilizing protein	Mus musculus	56-60
2370855-12	1990	At 0.3 M KCl, a fraction eluted from the DE 52 column that was also able to fully restore the EDRF/NO-synthesizing activity.	Potassium Chloride	9-12	alpha hemoglobin stabilizing protein	Mus musculus	94-98
35092867-5	2022	This tBHQ-induced increase in AHSP expression was also observed in Ter119+ mouse erythroblasts at each individual stage during terminal erythroid differentiation.	2-tert-butylhydroquinone	5-9	alpha hemoglobin stabilizing protein	Mus musculus	30-34
1671745-2	1991	It has been proposed that NH2OH is a putative intermediate in the biochemical pathway for the generation of nitric oxide (NO)/endothelium-derived relaxing factor (EDRF) from L-arginine.	Hydroxylamine	26-31	alpha hemoglobin stabilizing protein	Mus musculus	163-167
1671745-2	1991	It has been proposed that NH2OH is a putative intermediate in the biochemical pathway for the generation of nitric oxide (NO)/endothelium-derived relaxing factor (EDRF) from L-arginine.	Nitric Oxide	108-120	alpha hemoglobin stabilizing protein	Mus musculus	163-167
1671745-2	1991	It has been proposed that NH2OH is a putative intermediate in the biochemical pathway for the generation of nitric oxide (NO)/endothelium-derived relaxing factor (EDRF) from L-arginine.	Arginine	174-184	alpha hemoglobin stabilizing protein	Mus musculus	163-167
2370855-3	1990	The synthesis of this substance could be stimulated with the receptor agonist neurotensin (10 microM) or by addition of the EDRF/NO substrate L-arginine (100 microM).	Arginine	142-152	alpha hemoglobin stabilizing protein	Mus musculus	124-128
2370855-4	1990	In Ca2(+)-free Locke"s solution, stimulation of EDRF/NO production by both neurotensin and L-arginine was abolished.	Arginine	91-101	alpha hemoglobin stabilizing protein	Mus musculus	48-52
2370855-7	1990	L-Arginine and NADPH were required for maximal synthesis of EDRF/NO by the enzyme(s).	Arginine	0-10	alpha hemoglobin stabilizing protein	Mus musculus	60-64
2370855-7	1990	L-Arginine and NADPH were required for maximal synthesis of EDRF/NO by the enzyme(s).	NADP	15-20	alpha hemoglobin stabilizing protein	Mus musculus	60-64
2370855-8	1990	The synthesis of EDRF/NO was inhibited by the following antagonists of calmodulin-regulated functions (with the approximate IC50 values given in parentheses): calmidazolium (7 microM), trifluoperazine (10 microM), fendiline (80 microM), W-7 (N-[6-aminohexyl]-5-chloro-1-naphthalenesulfonamide) (120 microM), and compound 48/80 (3 micrograms/ml).	calmidazolium	159-172	alpha hemoglobin stabilizing protein	Mus musculus	17-21
2370855-8	1990	The synthesis of EDRF/NO was inhibited by the following antagonists of calmodulin-regulated functions (with the approximate IC50 values given in parentheses): calmidazolium (7 microM), trifluoperazine (10 microM), fendiline (80 microM), W-7 (N-[6-aminohexyl]-5-chloro-1-naphthalenesulfonamide) (120 microM), and compound 48/80 (3 micrograms/ml).	Trifluoperazine	185-200	alpha hemoglobin stabilizing protein	Mus musculus	17-21
2370855-8	1990	The synthesis of EDRF/NO was inhibited by the following antagonists of calmodulin-regulated functions (with the approximate IC50 values given in parentheses): calmidazolium (7 microM), trifluoperazine (10 microM), fendiline (80 microM), W-7 (N-[6-aminohexyl]-5-chloro-1-naphthalenesulfonamide) (120 microM), and compound 48/80 (3 micrograms/ml).	Fendiline	214-223	alpha hemoglobin stabilizing protein	Mus musculus	17-21
2370855-8	1990	The synthesis of EDRF/NO was inhibited by the following antagonists of calmodulin-regulated functions (with the approximate IC50 values given in parentheses): calmidazolium (7 microM), trifluoperazine (10 microM), fendiline (80 microM), W-7 (N-[6-aminohexyl]-5-chloro-1-naphthalenesulfonamide) (120 microM), and compound 48/80 (3 micrograms/ml).	W 7	237-240	alpha hemoglobin stabilizing protein	Mus musculus	17-21
2370855-8	1990	The synthesis of EDRF/NO was inhibited by the following antagonists of calmodulin-regulated functions (with the approximate IC50 values given in parentheses): calmidazolium (7 microM), trifluoperazine (10 microM), fendiline (80 microM), W-7 (N-[6-aminohexyl]-5-chloro-1-naphthalenesulfonamide) (120 microM), and compound 48/80 (3 micrograms/ml).	W 7	242-292	alpha hemoglobin stabilizing protein	Mus musculus	17-21
2174096-9	1990	These data suggest that in these arterioles a portion of the response to GMP, but not to AMP, is controlled by endothelium and may reflect a role for guanylate cyclase/GMP in the synthesis/-release of an EDRF.	guanosine 5'-monophosphorothioate	73-76	alpha hemoglobin stabilizing protein	Mus musculus	204-208
2155150-4	1990	Production of the EDRF-like factor was dependent on L-arginine and NADPH.	Arginine	52-62	alpha hemoglobin stabilizing protein	Mus musculus	18-22
2155150-4	1990	Production of the EDRF-like factor was dependent on L-arginine and NADPH.	NADP	67-72	alpha hemoglobin stabilizing protein	Mus musculus	18-22
2155150-6	1990	The production of the EDRF-like activity was inhibited by the L-arginine analogs, NG-monomethyl-L-arginine and NG-nitro-L-arginine, with apparent Ki values of 1.0 and 0.3 microM, respectively.	Arginine	62-72	alpha hemoglobin stabilizing protein	Mus musculus	22-26
2155150-6	1990	The production of the EDRF-like activity was inhibited by the L-arginine analogs, NG-monomethyl-L-arginine and NG-nitro-L-arginine, with apparent Ki values of 1.0 and 0.3 microM, respectively.	omega-N-Methylarginine	82-106	alpha hemoglobin stabilizing protein	Mus musculus	22-26
2155150-6	1990	The production of the EDRF-like activity was inhibited by the L-arginine analogs, NG-monomethyl-L-arginine and NG-nitro-L-arginine, with apparent Ki values of 1.0 and 0.3 microM, respectively.	Nitroarginine	111-130	alpha hemoglobin stabilizing protein	Mus musculus	22-26
2634248-3	1989	N omega-Nitro-L-arginine and NG-monomethyl-L-arginine, two inhibitors of EDRF synthesis, markedly attenuated the relaxations.	Nitroarginine	0-24	alpha hemoglobin stabilizing protein	Mus musculus	73-77
2634248-3	1989	N omega-Nitro-L-arginine and NG-monomethyl-L-arginine, two inhibitors of EDRF synthesis, markedly attenuated the relaxations.	omega-N-Methylarginine	29-53	alpha hemoglobin stabilizing protein	Mus musculus	73-77
2508448-2	1989	Endothelium-derived relaxing factor (EDRF) which has been identified as nitric oxide (NO) has been reported to inhibit platelet aggregation.	Nitric Oxide	72-84	alpha hemoglobin stabilizing protein	Mus musculus	0-35
2508448-2	1989	Endothelium-derived relaxing factor (EDRF) which has been identified as nitric oxide (NO) has been reported to inhibit platelet aggregation.	Nitric Oxide	72-84	alpha hemoglobin stabilizing protein	Mus musculus	37-41
22287545-3	2012	However, AHSP also stimulates autooxidation of alphaO(2) subunit and its rapid conversion to a partially unfolded bishistidyl hemichrome structure.	bishistidyl hemichrome	114-136	alpha hemoglobin stabilizing protein	Mus musculus	9-13
22287545-9	2012	Together, our findings indicate that the ability of AHSP to stabilize nascent alpha chain folding intermediates prior to hemin reduction and incorporation into adult Hemoglobin A is physiologically more important than AHSP interactions with ferrous alphaO(2) subunits.	Hemin	121-126	alpha hemoglobin stabilizing protein	Mus musculus	52-56
21980127-1	2011	RATIONALE: Nitric oxide, the classic endothelium-derived relaxing factor (EDRF), acts through cyclic GMP and calcium without notably affecting membrane potential.	Nitric Oxide	11-23	alpha hemoglobin stabilizing protein	Mus musculus	37-72
21767645-3	2012	Recently, the one electron redox variant of NO, nitroxyl anion (NO(-)) has emerged as an endothelium-derived relaxing factor (EDRF) and a candidate for endothelium-derived hyperpolarizing factor (EDRF).	oxoazanide	48-62	alpha hemoglobin stabilizing protein	Mus musculus	126-130
21767645-3	2012	Recently, the one electron redox variant of NO, nitroxyl anion (NO(-)) has emerged as an endothelium-derived relaxing factor (EDRF) and a candidate for endothelium-derived hyperpolarizing factor (EDRF).	oxoazanide	48-62	alpha hemoglobin stabilizing protein	Mus musculus	152-194
21767645-3	2012	Recently, the one electron redox variant of NO, nitroxyl anion (NO(-)) has emerged as an endothelium-derived relaxing factor (EDRF) and a candidate for endothelium-derived hyperpolarizing factor (EDRF).	oxoazanide	48-62	alpha hemoglobin stabilizing protein	Mus musculus	196-200
21980127-1	2011	RATIONALE: Nitric oxide, the classic endothelium-derived relaxing factor (EDRF), acts through cyclic GMP and calcium without notably affecting membrane potential.	Nitric Oxide	11-23	alpha hemoglobin stabilizing protein	Mus musculus	74-78
21980127-1	2011	RATIONALE: Nitric oxide, the classic endothelium-derived relaxing factor (EDRF), acts through cyclic GMP and calcium without notably affecting membrane potential.	Calcium	109-116	alpha hemoglobin stabilizing protein	Mus musculus	37-72
21980127-1	2011	RATIONALE: Nitric oxide, the classic endothelium-derived relaxing factor (EDRF), acts through cyclic GMP and calcium without notably affecting membrane potential.	Calcium	109-116	alpha hemoglobin stabilizing protein	Mus musculus	74-78
21980127-2	2011	A major component of EDRF activity derives from hyperpolarization and is termed endothelium-derived hyperpolarizing factor (EDHF).	1-hexadecyl-2-acetyl-glycero-3-phosphocholine	116-122	alpha hemoglobin stabilizing protein	Mus musculus	21-25
21980127-2	2011	A major component of EDRF activity derives from hyperpolarization and is termed endothelium-derived hyperpolarizing factor (EDHF).	edhf	124-128	alpha hemoglobin stabilizing protein	Mus musculus	21-25
21980127-3	2011	Hydrogen sulfide (H(2)S) is a prominent EDRF, since mice lacking its biosynthetic enzyme, cystathionine gamma-lyase (CSE), display pronounced hypertension with deficient vasorelaxant responses to acetylcholine.	Hydrogen Sulfide	0-16	alpha hemoglobin stabilizing protein	Mus musculus	40-44
21980127-3	2011	Hydrogen sulfide (H(2)S) is a prominent EDRF, since mice lacking its biosynthetic enzyme, cystathionine gamma-lyase (CSE), display pronounced hypertension with deficient vasorelaxant responses to acetylcholine.	Hydrogen Sulfide	18-23	alpha hemoglobin stabilizing protein	Mus musculus	40-44
21980127-3	2011	Hydrogen sulfide (H(2)S) is a prominent EDRF, since mice lacking its biosynthetic enzyme, cystathionine gamma-lyase (CSE), display pronounced hypertension with deficient vasorelaxant responses to acetylcholine.	Acetylcholine	196-209	alpha hemoglobin stabilizing protein	Mus musculus	40-44
20815047-2	2010	Alpha hemoglobin stabilizing protein (AHSP) is a molecular chaperone that binds free alpha-globin to promote its folding and inhibit its ability to produce damaging reactive oxygen species.	Reactive Oxygen Species	165-188	alpha hemoglobin stabilizing protein	Mus musculus	0-36
20815047-2	2010	Alpha hemoglobin stabilizing protein (AHSP) is a molecular chaperone that binds free alpha-globin to promote its folding and inhibit its ability to produce damaging reactive oxygen species.	Reactive Oxygen Species	165-188	alpha hemoglobin stabilizing protein	Mus musculus	38-42
20063986-10	2010	Significantly, serum iron concentration was remarkably reduced as compared with that of h-ahsp(-)/beta(IVS-2-654+) mice (43.2 +/- 14.9 vs. 82.4 +/- 12.9 microM), and iron deposition in the liver was decreased in h-ahsp(+)/beta(IVS-2-654+) mice.	Iron	21-25	alpha hemoglobin stabilizing protein	Mus musculus	214-218